Eaton Vance Management Zai Lab LTD Transaction History

Eaton Vance Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$27.77 - $64.4 $6,109 - $14,168	-220 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$54.9 - $105.21 $28,273 - $54,183	-515 Reduced 70.07%	220 $14,000
Q3 2021 Nov 15, 2021	SELL	$105.0 - $178.37 $116,235 - $197,455	-1,107 Reduced 60.1%	735 $77,000
Q2 2021 Aug 16, 2021	BUY	$125.11 - $180.0 $140,748 - $202,500	1,125 Added 156.9%	1,842 $326,000
Q1 2021 May 17, 2021	BUY	$126.27 - $191.71 $90,535 - $137,456	717 New	717 $96,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.95B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.